Skip to main content

Advertisement

Table 1 Baseline characteristics of the intention-to-treat (ITT) population with osteoarthritis of the knee

From: Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]

   Risedronate  
Characteristic Placebo (n = 98) 5 mg/day (n = 96) 15 mg/day (n = 90) P
Age (years) 63.2 (0.82) 62.9 (0.90) 63.8 (0.88) 0.652a
Height (cm) 164.3 (0.90) 165.3 (0.97) 165.1 (0.93) 0.614a
Body mass index (kg/m2) 29.2 (0.38) 29.0 (0.40) 29.2 (0.42) 0.799a
Sex (no. (%))     0.307b
   Male 34 (35%) 40 (42%) 41 (46%)  
   Female 64 (65%) 56 (58%) 49 (54%)  
Post-menopausal (no. (%)) 54 (84%) 49 (88%) 43 (88%) 0.985b
Years since menopause 14.4 (1.22) 16.5 (1.57) 17.4 (1.42) 0.273a
Oestrogen or SERM use (no. (%)) 18 (28%) 15 (27%) 10 (20%) 0.380b
Race (no.)     0.385b
   Asian Oriental 1 0 0  
   Asian Indian 1 0 2  
   Caucasian 96 96 88  
Joint-space width (mm) 3.03 (0.05) 2.95 (0.05) 3.01 (0.06) 0.577a
WOMAC – weighted total score 50.3 (2.0) 46.1 (2.0) 49.4 (2.4) 0.281a
Use of walking aids (no. (%)) 16 (16) 22 (23) 12 (13) 0.224b
uCTX-II (ng/mmol creatinine) 312.5 (19.9) 328.9 (29.7) 340.1 (24.0) 0.748a
uNTX-I (nmol/mmol creatinine) 40.3 (2.8) 42.3 (4.5) 38.6 (2.2) 0.954a
  1. Unless indicated otherwise, values are means (standard errors of the mean). aKruskal–Wallis test; bFisher exact test. SERM, selective oestrogen receptor modulator; uCTX-II, urinary C-terminal crosslinking telopeptide of type II collagen; uNTX-I, urinary N-terminal crosslinking telopeptide of type I collagen; WOMAC, Western Ontario and McMaster Universities osteoarthritis index.